C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 413/06 (2006.01) A61K 31/42 (2006.01) A61K 31/425 (2006.01) A61K 31/435 (2006.01) A61K 31/495 (2006.01) A61K 31/53 (2006.01) A61K 31/535 (2006.01) A61K 31/54 (2006.01) A61K 31/55 (2006.01) A61K 31/675 (2006.01) A61K 31/695 (2006.01) C07D 413/12 (2006.01) C07D 413/14 (2006.01) C07D 417/00 (2006.01) C07D 417/06 (2006.01) C07D 453/02 (2006.01) C07D 471/04 (2006.01) C07D 473/00 (2006.01) C07D 475/00 (2006.01) C07D 487/08 (2006.01) C07D 513/04 (2006.01) C07F 7/10 (2006.01) C07F 9/6558 (2006.01)
Patent
CA 2221980
This invention relates to novel heterocycle compounds including but not limited to 3-[3-[3-(imidazolin-2-yl amino)propyloxy]isoxazol--5-ylcarbonylamino]-2- (benzyloxycarbonylamino)-propionic acid, which are useful as antagonists of the .alpha.v.beta.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.
Cette invention se rapporte à de nouveaux composés hétérocycliques comprenant notamment, mais pas exclusivement, l'acide 3-[3-[3-(imidazoline-2-yl- amino)propyloxy]isoxasol-5-ylcarbonylamino]-2-(benzyloxycarbonylamino)-propionique et qui sont utilisés comme antagonistes des récepteurs alpha v beta b3 et de l'intégrine apparentée. L'invention se rapporte également aux compositions pharmaceutiques contenant ces composés, aux procédés de préparation et d'utilisation de ces composés, seuls ou associés à d'autres agents thérapeutiques et destinés à être utilisés dans des procédés d'inhibition de l'adhésion cellulaire et de traitement de troubles angiogéniques, des inflammations, de la déperdition osseuse, des tumeurs, des métastases, de la thrombose et d'autres états apparentés à l'agrégation cellulaire.
Batt Douglas Guy
Jadhav Prabhakar Kondaji
Pitts William John
Smallheer Joanne Marie
Voss Matthew Ernst
Bristol-Myers Squibb Pharma Company
Dimock Stratton Llp
The Dupont Merck Pharmaceutical Company
LandOfFree
Isoxazoline and isoxazole derivatives as integrin receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoxazoline and isoxazole derivatives as integrin receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoxazoline and isoxazole derivatives as integrin receptor... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1409247